NCT03400501View on ClinicalTrials.gov

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Insulin Degludec

Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose

DRUG

Insulin Glargine

Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose

Trial Locations (1)

06511

Yale University, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03400501 - Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin | Biotech Hunter | Biotech Hunter